The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Soap; cosmetic soaps; dentifrices; toilet water; lotions for
cosmetic purposes; skin lotion; hair lotion; body lotion;
wave-set lotions; perfumery, other than perfumes for
personal use; incense; false nails; false eyelashes.
4.
PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
The present disclosure relates to processes for preparing synthetic intermediates for the synthesis of isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity.
C07D 309/06 - Radicals substituted by oxygen atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
Provided is a novel chimeric antigen receptor. This chimeric antigen receptor includes an scFv region having such a structure that the C-terminus of a heavy-chain variable region and the N-terminus of a light-chain variable region are linked to each other through a linker, wherein: the heavy-chain variable region includes a heavy-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 2, and/or a heavy-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 3, and/or the light-chain variable region includes a light-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 5, a light-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 6, and/or a light-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 7; and the number of amino acid residues constituting the linker is 15-50.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present disclosure relates to pharmaceutical compositions comprising a solid dispersion comprising a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, as well as methods of treatment.
This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 9/00 - Medicinal preparations characterised by special physical form
A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):
A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):
A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):
where R1 is halogen, aryl, aryloxy, or lower alkyl optionally substituted with one or more halogen atoms; R2 is hydrogen, halogen, lower alkyl, or lower alkoxy; and m=1 to 3, provided that when m is 2 or 3, each R1 is the same or different.
Disclosed are pyrazolopyridine or pyrazolopyrimidine compounds, or salts thereof, with colony-stimulating factor-1 receptor (CSF1R) inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with CSF1R, and methods of preparing said compounds, or salts thereof. Provided include a compound represented by Formula [I], or a salt thereof, wherein R1is hydrogen, etc.; R21and R22are hydrogen, or R21and R22together with the adjacent heterocyclic form a bridged bicyclic ring; R3is -L31-R31optionally substituted with one or more R32, or R31optionally substituted with one or more R32; L31is -C(=O)-, etc.; R311-61-6 alkyl, etc.; R32is each independently halogen, etc.; and X is CR1 or N; medical use thereof, and methods of preparation thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention discloses administering pharmaceutical compositions in combination, one of which is a pharmaceutical composition containing a tolinapant drug, and the other of which is a pharmaceutical composition containing an immune cell modified to express a chimeric antigen receptor or a recombinant T-cell receptor.
A compound represented by formula [I]:
A compound represented by formula [I]:
A compound represented by formula [I]:
wherein R12, R13, R14, R15, and R16 are the same or different and are each hydrogen, halogen, C1-6 alkyl optionally substituted with halogen, or C1-6 alkoxy optionally substituted with halogen; R21, R22, and R23 are the same or different and are each hydrogen, halogen, C1-6 alkyl optionally substituted with halogen, C1-6 alkoxy optionally substituted with halogen, sulfanyl optionally substituted with halogen, nitro, or cyano; R3 is C1-6 alkyl or the like; and X− is an anion.
C07D 219/04 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
C07C 37/60 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by oxidation reactions introducing directly a hydroxy group on a CH-group belonging to a six-membered aromatic ring with the aid of other oxidants than molecular oxygen or their mixtures with molecular oxygen
Provided is a means that is capable of preventing initial excessive release of an active ingredient, and that allows for sustained release of a pharmaceutically active amount of the active ingredient over a long period of time.
An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s−1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s−1, as measured.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of central nervous system diseases and
disorders.
18.
PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF
The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
Provided is a solution suitable for oral administration of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one(compound (I)) or a salt thereof. A solution for oral administration containing compound (I) or a salt thereof, and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid and having pH 2.5-4.5.
Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I):
Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I):
Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I):
wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
The present disclosure provides a composition for a treatment for a wound, and the like. N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-oxazol-4-yl}methyl)-2-ethoxybenzamide or its salt is useful as an active ingredient of a composition for a treatment for a wound.
Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for medical purposes; syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing, and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems
An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.
A novel means for improving sleep quality etc. is provided. Provided is a composition for sleep quality improvement that contains kaempferol and/or a glycoside thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof,
Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof,
Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof,
in the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is —C(═O)—NH—, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present application provides a phytin with improved solubility in water, wherein the phytin comprises calcium and/or magnesium with specific of molar ratios to phytic acid.
Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
35.
PHARMACEUTICAL COMPOSITIONS INCLUDING TOLINAPANT AND PACKAGING
The present disclosure relates generally pharmaceutical compositions comprising tolinapant or a pharmaceutically acceptable salt thereof, as well as methods of treatment, and packaging of the dosage form.
The disclosure provides a frozen dessert composition including (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition. The disclosure also provides a method of manufacturing a frozen dessert composition including mixing the following components with water; (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition.
A23G 9/34 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition characterised by carbohydrates used, e.g. polysaccharides
A23G 9/38 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing peptides or proteins
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
B65D 85/60 - Containers, packaging elements or packages, specially adapted for particular articles or materials for sweets or like confectionery products
37.
METHODS OF DISPERSING ARIPIPRAZOLE INJECTABLE PREPARATIONS
The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of long-acting injectable preparations comprising aripiprazole or a salt thereof, comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Anti-psychotics; central nervous system stimulants; central nervous system depressants; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of bipolar disorder; pharmaceutical preparations for the treatment of irritability associated with autistic disorder.
41.
COMPOSITION FOR TREATING AND/OR PREVENTING HEARING IMPAIRMENT
Provided is: a composition for treating and/or preventing hearing impairment, the composition containing an asparagus extract; or a composition for maintaining and/or improving hearing function, the composition containing an asparagus extract.
The present invention relates to a safe and effective therapeutic agent for nonalcoholic steatohepatitis (NASH), more specifically, a therapeutic, preventative and/or diagnostic medicament for NASH, comprising 5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile, represented by the following structural formula or a pharmaceutically acceptable salt thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.
The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.
The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.
Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]:
Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]:
Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]:
wherein each symbol is as defined in the description, or a salt thereof.
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1):
The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1):
wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder, binge eating disorder and major depressive disorder; pharmaceutical preparations, namely, smoking cessation preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder; pharmaceutical preparations for the prevention and treatment of smoking habits and addictions.
52.
INFORMATION PROVISION METHOD FOR PREDICTING HEALTH CONDITION OF CONSUMER AND SUPPORTING HEALTH MAINTENANCE AND IMPROVEMENT
A technique calls attention for a subject to a predetermined disease or to a disorder that is accompanied by a symptom obstructing the subject's daily life. An information providing method includes acquiring personal data of a target customer, determining a segmentation to which the customer belongs based on the data and a classification criterion that is prepared in advance, from plural segmentations each indicating a class that corresponds to the degree of a health condition, and providing health information that corresponds to the segmentation to the customer. The personal data includes pieces of unique data on the target customer. At least one of the pieces of unique data is symptom data that reflects a health symptom of the target customer. The segmentations are classified corresponding to the degrees of the health symptom, and each of the segmentations is correlated with health information prepared in advance corresponding to the health symptom.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
53.
METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
The present disclosure is directed to a method of dose initiation for an aripiprazole treatment to a patient in need thereof; the patient is administered two, separate 100 to 500 mg injections of an aripiprazole intramuscular (IM) depot formulation at separate gluteal and/or deltoid injection sites, and a single dose of oral aripiprazole. The administration occurs on a first day of the treatment.
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:
wherein each symbol is as defined in the description, or a salt thereof, having PAR2 inhibitory activity, and a pharmaceutical composition comprising the same.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
An object of the present invention is to a new method of producing a kidney organoid. The method for producing a kidney organoid is characterized by comprising culturing an early kidney organoid with a medium containing an RXR agonist and a PPAR agonist, wherein the kidney organoid includes matured proximal tubule cells.
The present invention relates to a compound of formula (I) which can selectively inhibit the differentiation from hematopoietic stem cell toward megakaryocytes.
An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
58.
BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS
The invention provides a compound of formula (0):
The invention provides a compound of formula (0):
or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein:
n is 1 or 2;
X is CH or N;
Y is selected from CH and C—F;
Z is selected from C—Rz and N;
R1 is selected from:
-(Alk1)t-Cyc1; wherein t is 0 or 1;
Optionally substituted C1-6 acyclic hydrocarbon groups
R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms;
R3 is hydrogen or a group L1-R7;
R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and
R4a is selected from hydrogen and a C1-3 alkyl group;
wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein;
provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.
The invention provides a compound of formula (0):
or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein:
n is 1 or 2;
X is CH or N;
Y is selected from CH and C—F;
Z is selected from C—Rz and N;
R1 is selected from:
-(Alk1)t-Cyc1; wherein t is 0 or 1;
Optionally substituted C1-6 acyclic hydrocarbon groups
R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms;
R3 is hydrogen or a group L1-R7;
R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and
R4a is selected from hydrogen and a C1-3 alkyl group;
wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein;
provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.
The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Provided is a novel therapeutic agent for central nervous system diseases. More specifically, provided is a compound represented by formula (I) (in the formula, R1and R2each independently denote -Oi, -OR4or -NR4NaR4Nb, R3denotes hydrogen or an alkyl group, R4, R4Naand R4Nb22-) in alkyl groups denoted by R4, R4Naand R4Nbmay be replaced by -O-, -S-, -CO-, -NH-, -SiRsiaRsib- or -(CO)O-, and in a case where R1and R2both denote -OR4, R1and R2may be the same as, or different from, each other, and in a case where R1and R2both denote -NR4NaR4Nb, R1and R2 may be the same as, or different from, each other), or a salt of said compound.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
60.
RESPONSE-BASED DOSING FOR TREATING CANCER WITH A HYPOMETHYLATING AGENT AND CEDAZURIDINE
Provided according to some embodiments of the invention are methods of treating cancer in a subject in need thereof that include administering to the subject a first amount of a hypomethylating agent (e.g., decitabine) and a first amount of cedazuridine in a first dosing cycle; measuring a response of the cancer to the first dosing cycle; and administering a second, reduced amount of the hypomethylating agent and a second, reduced amount of cedazuridine in subsequent dosing cycle(s) if the response of the cancer to the first dosing cycle meets a predetermined criterion.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 405/02 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present disclosure is directed to methods of dose initiation for an aripiprazole treatment to a patient in need thereof by administering two, separate injections of aripiprazole with a first aripiprazole injection of a long acting injectable (LAI) and a second aripiprazole injection of a once-monthly injectable (AOM) on a first day of the aripiprazole treatment, and a single dose of oral aripiprazole. Maintenance dosing occurs about two months after the first day of the aripiprazole treatment using a maintenance dose of the LAI. The present methods are applicable to both the deltoid and gluteal administration sites.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
The present invention provides a production method for megakaryocytes that includes a step for forcing hematopoietic precursor cells to express a cancer gene, a homeobox gene, and an apoptosis-suppressing gene and culturing the cells. The present invention also provides a kit for producing megakaryocytes, mature megakaryocytes, or platelets that includes a vector that includes a cancer gene, a homeobox gene, and an apoptosis-suppressing gene.
The present application provides a method for improvement in physical activity efficiency, a method for reducing fatigue, and a method for improving dynamic/kinetic visual acuity, comprising administering a composition comprising a kaempferol analog to a subject in need thereof.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention provides an organoid characterized by comprising a layered structure of a sheet-like retinal pigment epithelial cell layer and a layer containing visual cells. The present invention also provides a method for producing an organoid, the method comprising: (1) a step for inducing differentiation of retinal progenitor cells from pluripotent stem cells; and (2) a step for carrying out adherent culture of the obtained retinal progenitor cells using a medium containing at least either a serum-free supplement or serum.
The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of long-acting injectable preparations comprising aripiprazole or a salt thereof, comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.
The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of containers comprising long-acting injectable preparations comprising aripiprazole or a salt thereof, the methods comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
75.
COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF
The present disclosure relates to compounds that target mutations in p53, to pharmaceutical compositions comprising said compounds, and to the use of said compounds and compositions as medicaments, such as in the treatment of cancer, and related aspects. Such compounds may bind, stabilise, and restore the level of correctly folded p53 by stabilising an active p53 conformation and restoring wild type-like transcriptional function of mutant p53.
The present application relates to novel compounds of formula (I) which are prodrugs of brexpiprazole. The novel compounds of the invention, upon administration to a subject, undergo chemical conversion by one or more metabolic processes to release an active pharmacological agent in vivo. Brexpiprazole, sold under the Rexulti (registered trademark), is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults and the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
A61P 25/00 - Drugs for disorders of the nervous system
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The invention provides DNA damage response (DDR) pathway genes and their gene products as biomarkers to predict effective treatment of cancer using an MDM2 antagonist. Identifying one or more DDR pathway biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. In particular, the DDR pathway comprises one or more genes from: the homologous recombination repair (HRR) pathway; the non-homologous end joining (NHEJ) pathway; the mismatch repair (MMR) pathway; the Fanconi
The present disclosure relates generally to methods for the preparation of Compound (I).
The present disclosure relates generally to methods for the preparation of Compound (I).
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07C 67/10 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07D 209/46 - Iso-indolesHydrogenated iso-indoles with an oxygen atom in position 1
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides a new azabicyclo[3.1.0]hexane compound that is represented by the following formula:
The present invention provides a new azabicyclo[3.1.0]hexane compound that is represented by the following formula:
The present invention provides a new azabicyclo[3.1.0]hexane compound that is represented by the following formula:
and that is for use in treating central nervous system (CNS) disorders. In the formula, X represents —C(═)—O— or the like, and R represents H, an optionally substituted C1-C18 alkyl, or the like.
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability.
This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability.
The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate;
and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
86.
TAU SPLICE-SWITCHING OLIGONUCLEOTIDE, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING TAU-RELATED DISEASE
The present disclosure includes: a splice-switching oligonucleotide binding to intron 1B of TAU pre-mRNA; and a pharmaceutical composition for treating or preventing a TAU-related disease, the pharmaceutical composition containing the splice-switching oligonucleotide.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure provides a composition for hair cleansing that contains sodium taurine lauroyl methyl-β-alaninate, lauroamidopropyl betaine, and cocamide methyl MEA, the composition having a great effect in imparting firmness and resilience to hair.
A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
The present invention provides a compound or a salt thereof for use in preparation of a linker with which it is easy to acquire an antibody-drug conjugate that has a uniform structure and that is stable in blood. As the compound or a salt thereof, disclosed is a compound represented by general formula [ML-I] or a salt thereof. [Wherein: X represents a leaving group; R1and R21-61-61-6 alkylene-R11that is optionally substituted with one or more substituent groups (where R1and R2would not simultaneously be hydrogen); alternatively, R1and R21-61-6 alkylene-R11that is optionally substituted with additional one or more substituent groups; and R113322 or an ester group thereof.]
C07C 243/14 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07C 309/13 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of central nervous system diseases and disorders, containing electronic chips which transmit information about drug ingestion by the patient
92.
LOW POWER RECEIVER FOR IN VIVO CHANNEL SENSING AND INGESTIBLE SENSOR DETECTION WITH WANDERING FREQUENCY
A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.
A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
G01C 22/00 - Measuring distance traversed on the ground by vehicles, persons, animals or other moving solid bodies, e.g. using odometers or using pedometers
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
93.
DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE
An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 9/00 - Medicinal preparations characterised by special physical form
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]:
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]:
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]:
wherein ring A, ring B, R1, R2, R3, R4, n, and X are as defined above, or a salt thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided is a method for producing a quinolone compound represented by a formula (14), the method comprising reacting a compound represented by a formula (10) with a compound represented by a formula (13) that is produced by reacting a compound represented by a formula (12) with a compound represented by a formula (a) and a compound represented by a formula (b).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Non-medicated soaps and detergent soaps; Cosmetics and non-medicated toiletry preparations; Facial washes; Non-medicated facial soaps; Non-medicated skin serums; Toilet waters; Non-medicated skin lotions; Beauty milks; Non-medicated skin creams; Beauty creams for the skin around eyes; Non-medicated lip care preparations; Beauty masks; Paper soaps for personal use; Pre-moistened cosmetic tissues and wipes; Make up removing preparations; Make-up primers; Sunblock preparations for personal use; Non- medicated bath preparations Pharmaceutical agents for epidermis; Medicated skin serums; Medicated skin lotions; Medicated skin milk in the nature of moisturizing milk; Medicated skin creams; Medicated lip care preparations, namely lip balms and lip creams; Medicated sunburn ointments and lotions; pharmaceutical preparations for treating sunburns; Medicated bath preparations; Dietetic food adapted for medical purposes; Dietetic beverages adapted for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; diagnostic reagents for medical
use; diagnostic test reagents for medical purposes;
diagnostic biomarker reagents for medical purposes. Medical apparatus and instruments; diagnostic apparatus for
medical purposes; testing apparatus for medical purposes;
medical diagnostic apparatus for detecting, measuring and
testing biomarkers.
98.
INJECTION DEVICE WITH INJECTION COMPLETION INDICATOR
In an aspect, the present invention is directed to an injection device. The injection device includes a pneumatic piston chamber and a pneumatic piston slidably positioned within the pneumatic piston chamber; a dose chamber and an injectate piston slidably positioned within the dose chamber; and an injection completion indicator comprising a window into the piston chamber or dose chamber, wherein the injection completion indicator is aligned with a portion of the pneumatic piston chamber or the dose chamber. In another aspect, the present invention is directed to a method of administering an injection to a subject using the injection device of the invention.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
99.
Centanafadine pharmaceutical formulations, and methods of making and using same
Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 25/00 - Drugs for disorders of the nervous system
100.
AMORPHOUS FORM AND COMPOSITION CONTAINING SAID AMORPHOUS FORM
Provided are an amorphous solid dispersion containing compound (I), an amorphous form containing compound (I) and an organic acid, an amorphous solid dispersion containing the amorphous form, a pharmaceutical composition containing the amorphous form or the amorphous solid dispersion, and preparation methods for these.
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 9/00 - Medicinal preparations characterised by special physical form
